levetiracetam and Syncope

levetiracetam has been researched along with Syncope* in 4 studies

Other Studies

4 other study(ies) available for levetiracetam and Syncope

ArticleYear
Treatment of drop attacks: Anti-seizure drug choices of pediatric neurologists in Saudi Arabia.
    Neurosciences (Riyadh, Saudi Arabia), 2023, Volume: 28, Issue:3

    To evaluate Epileptic drop attacks (EDAs) treatment options among pediatric neurologists in Saudi Arabia (SA) and to develop a recommendation scheme for the management of EDAs in SA. Epileptic drop attacks are one of the most pharmaco-resistant epileptic seizures. The different approaches to EDA treatment are influenced by a variety of factors, including pharmaceutical availability, costs, side effects, treating physicians' experience and personal preferences.. This cross-sectional study was conducted online. A structured questionnaire that aimed to measure the therapeutic options for patients with EDA was electronically distributed to pediatric neurologists across SA. It contained 21 questions, and the data were collected in Excel sheets and analyzed.. Our study included a cohort of 71 pediatric neurologists from SA, of which male doctors represented 60%. Most of the participating pediatric neurologists had more than 10 years of experience in the field. We found that 77% of the included pediatric neurologists used valproic acid as a first-line drug in patients with EDA. Further, in the different case scenarios provided to participants, levetiracetam, clobazam, topiramate, and rufinamide were included in the initial management protocol for EDA.. The majority of pediatric neurologists in Saudi Arabia chose valproic acid and/or levetiracetam as the first line of treatment for EDA. These results highlight the need for an evidence-based clinical guidelines to treat EDA.

    Topics: Anticonvulsants; Child; Cross-Sectional Studies; Humans; Levetiracetam; Male; Neurologists; Saudi Arabia; Seizures; Syncope; Valproic Acid

2023
Presumed mitochondrial disease manifesting with recurrent syncopes.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:2

    Loss of consciousness may be due to neurological or cardiac involvement in mitochondrial disease, and is often difficult to attribute to either cause, as in the following case.. A 67-year-old man with hypertension, diabetes, elevated serum creatine kinase, glaucoma, optic atrophy, and vertigo had experienced recurrent losses of consciousness since 63 years of age. Diagnostic work-up revealed paroxysmal supraventricular arrhythmias, hyperlipidemia, steatosis hepatis, renal insufficiency, polyneuropathy, first-degree atrio-ventricular block, orthostasis, and cataract. From the age of 66 years, he developed tonic-clonic seizures. Electrocardiography loop recording showed some losses of consciousness as associated with supraventricular tachycardias and others with epileptic activity or arterial hypotension. Neurological investigations and muscle biopsy were indicative of mitochondrial disease with multisystem involvement. Losses of consciousness disappeared after catheter ablation and treatment with levetiracetam.. Recurrent loss of consciousness in mitochondrial disease may not only be due to arrhythmias but also seizure activity, or autonomic neuropathy. Arrhythmias, seizures, and polyneuropathy may have a common underlying cause affecting various tissues.

    Topics: Aged; Anticonvulsants; Autonomic Nervous System Diseases; Biopsy; Catheter Ablation; Electrocardiography; Epilepsy, Tonic-Clonic; Humans; Levetiracetam; Male; Mitochondrial Diseases; Piracetam; Recurrence; Syncope; Tachycardia, Supraventricular; Treatment Outcome

2014
Ictal asystole in epilepsy patients undergoing inpatient video-EEG monitoring.
    Neurosciences (Riyadh, Saudi Arabia), 2014, Volume: 19, Issue:4

    Ictal asystole (IA) is uncommonly diagnosed and has been implicated as a potential cause of sudden unexpected death in epilepsy. Sudden unexpected death in epilepsy is an increasingly recognizable condition and is more likely to occur in patients with medically intractable epilepsy and those suffering from convulsive epilepsy. We report 2 cases of recent onset of prolonged syncope and unrevealing cardiac work up. The inpatient video-EEG monitoring recorded left temporal ictal discharges followed by IA. Although the role of cardiac pacing is controversial in these patients, both patients had favorable outcome following cardiac pacemaker insertion. This report demonstrates the variability in IA pathophysiology and clinical manifestations. It also advocates that cardiac pacing might have a role in the management of IA.

    Topics: Aged; Anticonvulsants; Bradycardia; Electroencephalography; Epilepsy, Temporal Lobe; Female; Heart Arrest; Humans; Inpatients; Levetiracetam; Middle Aged; Monitoring, Physiologic; Pacemaker, Artificial; Phenytoin; Piracetam; Syncope; Video Recording

2014
Ventricular fibrillation in loop recorder memories in a patient with early repolarization syndrome.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2012, Volume: 14, Issue:1

    We report the first documentation of spontaneous ventricular fibrillation by a loop recorder in a patient with an ECG pattern of early repolarization (ER) in the inferior leads and presenting with syncope.

    Topics: Adolescent; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cyanosis; Defibrillators, Implantable; Electrocardiography; Humans; Levetiracetam; Male; Piracetam; Quinidine; Syncope; Treatment Outcome; Ventricular Fibrillation

2012